Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesMalignant neoplasms of eye, brain and other parts of central nervous systemICD-10-CM c69-malignant-neoplasm-of-eye-and-adnexa
    Ask Trek AI about this page

    ICD-10-CM Code For Malignant Neoplasm Of Eye And Adnexa: Group Overview

    The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code group C69 includes malignant tumors of the eye and adnexa, such as cancers of the eyelid, conjunctiva, cornea, choroid, retina, optic nerve, lacrimal system, and orbit. These ICD-10-CM diagnosis codes are used to document clinical encounters for ocular and periocular malignancies, capturing tumor site, laterality, and extent of local invasion when applicable. Accurate coding within the ICD-10-CM C69 group supports proper claim adjudication, complete clinical documentation, and appropriate reimbursement.

    Customize your policy alerts

    Sign up for ICD-10-CM Code For Malignant Neoplasm Of Eye And Adnexa: Group Overview policy alerts

    Get alerted when relevant policies change without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    ICD-10-CM C69: Malignant Neoplasm Of Eye And Adnexa Overview

    The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code group C69 captures malignant tumors originating in the eye and its surrounding adnexal structures, including the eyelid, conjunctiva, cornea, choroid, retina, optic nerve, lacrimal apparatus, and orbital tissues. These codes target ocular oncology and periocular malignancies affecting visual function and local structures. Accurate coding is important for clinical communication and for appropriate reimbursement determination tied to documented disease extent and treatment intensity.

    Table of contents

    Progress1 / 6

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    When to Use

    Use a code from this group when documenting a confirmed malignant tumor originating in the eye or periocular structures, with specification of the exact anatomical site and laterality when known. Select the most specific code available to reflect tumor location and any documented extension to adjacent structures for accurate clinical and billing records.

    ICD-10-CM Codes

    27 rows

    ICD-10-CM CodeDescription
    C69.00Malignant neoplasm of unspecified conjunctiva
    C69.01Malignant neoplasm of right conjunctiva
    C69.02Malignant neoplasm of left conjunctiva
    C69.10Malignant neoplasm of unspecified cornea
    C69.11Malignant neoplasm of right cornea
    C69.12Malignant neoplasm of left cornea
    C69.20Malignant neoplasm of unspecified retina
    C69.21Malignant neoplasm of right retina
    C69.22Malignant neoplasm of left retina
    C69.30Malignant neoplasm of unspecified choroid
    C69.31Malignant neoplasm of right choroid
    C69.32Malignant neoplasm of left choroid
    C69.40Malignant neoplasm of unspecified ciliary body
    C69.41Malignant neoplasm of right ciliary body
    C69.42Malignant neoplasm of left ciliary body
    C69.50Malignant neoplasm of unspecified lacrimal gland and duct
    C69.51Malignant neoplasm of right lacrimal gland and duct
    C69.52Malignant neoplasm of left lacrimal gland and duct
    C69.60Malignant neoplasm of unspecified orbit
    C69.61Malignant neoplasm of right orbit

    Showing 1–20 of 27

    DRG Codes

    2 rows

    DRG CodeDescription
    124Other Disorders of the Eye with MCC or Thrombolytic Agent
    125Other Disorders of the Eye without MCC

    Typical Clinical Scenarios

    • A middle-aged patient presents to ophthalmology with a progressive, pigmented mass on the conjunctiva causing irritation and decreased vision over several months; biopsy confirms invasive melanoma of the conjunctiva, and the patient is referred for staging and treatment planning. A code from this group is assigned to capture the malignant neoplasm of the conjunctival tissue. Typical codes: C69.0 is not in the provided list, so use the most specific available codes: C69.00, C69.01
    • An elderly patient arrives to the emergency department with sudden onset monocular vision loss and a painful, proptotic eye; imaging reveals an aggressive primary intraocular tumor involving the ciliary body extending into the orbit. An acute care diagnosis from this group is assigned to document the malignant intraocular neoplasm driving the emergent presentation and to guide urgent oncology/ophthalmology consultation. Typical codes: C69.3, using available specificity: C69.30, C69.31
    • A younger adult with a history of previously treated choroidal melanoma presents for routine surveillance and is found to have secondary glaucoma in the affected eye associated with tumor recurrence. The chronic complication is coded to reflect the underlying malignant neoplasm as a comorbidity contributing to the ocular complication and ongoing management. Typical codes: C69.2, selecting from the provided list: C69.20, C69.21

    Related Codes

    C70-MALIGNANT-NEOPLASM-OF-MENINGES

    ICD-10-CM Code For Malignant Neoplasm Of Meninges: Group Overview

    C71-MALIGNANT-NEOPLASM-OF-BRAIN

    ICD-10-CM Code For Malignant Neoplasm Of Brain: Group Overview

    C72-SPINAL-CORD-CRANIAL-NERVE-NEOPLASMS

    ICD-10-CM Code For Malignant Neoplasm Of Spinal Cord Cranial Nerves And Other Parts Of Central Nervous System: Group Overview

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.